HILLARY DU: Open Payments
NPI 1720631492 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,801 in 101 payments from 15 companies in 2025. Trend: 2023 $2,838 · 2024 $2,276 · 2025 $2,801
Food & beverage: $2,801
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $671 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $537 |
| E.R. Squibb & Sons, L.L.C. | 9 | $365 |
| Lundbeck LLC | 9 | $265 |
| Neurocrine BioSciences, Inc. | 8 | $223 |
| Teva Pharmaceuticals USA, Inc. | 7 | $204 |
| Alkermes, Inc. | 7 | $142 |
| Axsome Therapeutics, Inc. | 5 | $84 |
| Indivior Inc. | 3 | $79 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
Products named: VRAYLAR, CAPLYTA, COBENFY, REXULTI, INGREZZA, AUSTEDO XR, ARISTADA, Auvelity.
Industry payments across MA — which companies pay providers there.
